InsidersTradesSigma
Track the Nuvation Bio Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Nuvation Bio Inc. has published 52 public disclosures. Market capitalisation: €2.4bn. The latest transaction was disclosed on 21 August 2026 (Levée d'options). Among the most active insiders: Liu Dongfang. The full history is free.
52
Insider Decl.
n/a
Thresholds
€16m
15 ops.
Buy Volume
€58m
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Nuvation Bio Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$13.11.
41Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,091 of 29,063 companies
33.8
score / 100
Value18
Quality50
FCF yld-7.8%
Earn yld-8.8%
EV/EBITDA·
ROE-48%
Gross mgn85%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations52 total
100,000 shares@ US$1.87Class A Common StockSEC:0001521111-26-000005:0
100,000 shares@ US$7.0924Class A Common StockSEC:0001521111-26-000005:1
100,000 shares@ US$6.960.029% mcap100.0% of flowCOMMONSEC144:0001950047-26-008412
39,999 shares@ US$2.170.0042% mcap93.5% of flowClass A Common StockSEC:0002039891-26-000008:0
1 shares@ US$1.970.0000% mcap0.0% of flowClass A Common StockSEC:0002039891-26-000008:1
47,668 shares@ US$5.760.014% mcap100.0% of flowCOMMONSEC144:0001950047-26-006424
125,000 shares@ US$5.760.036% mcap100.0% of flowCommonSEC144:0001950047-26-006426
63,000 shares@ US$5.760.018% mcap100.0% of flowCOMMONSEC144:0001950047-26-006425
50,000 shares@ US$5.020.012% mcap64.6% of flowClass A Common StockSEC:0001937915-26-000004:1
36,750 shares@ US$2.930.0053% mcap36.9% of flowClass A Common StockSEC:0001369453-26-000006:0
36,750 shares@ US$5.01440.0092% mcap63.1% of flowClass A Common StockSEC:0001369453-26-000006:1
50,000 shares@ US$1.940.0048% mcap25.0% of flowClass A Common StockSEC:0001937915-26-000004:0
100,000 shares@ US$1.9412.4% of flowClass A Common StockSEC:0001369453-26-000005:1
200,000 shares@ US$4.517857.5% of flowClass A Common StockSEC:0001369453-26-000005:2
100,000 shares@ US$1.8711.9% of flowClass A Common StockSEC:0001369453-26-000005:0
50,761 shares0Class A Common StockSEC:0002001938-26-000004:0
150,000 shares@ US$2.9347.6% of flowClass A Common StockSEC:0001937915-25-000010:0
10,000 shares@ US$3.617.5% of flowClass A Common StockSEC:0001937915-25-000008:0
69,051 shares@ US$1.7441.0% of flowClass A Common StockSEC:0001521111-25-000006:0
20,000 shares@ US$1.877.8% of flowClass A Common StockSEC:0001937915-25-000006:0
200,000 shares@ US$1.87100.0% of flowClass A Common StockSEC:0001865826-25-000004:0
15,000 shares@ US$1.876.8% of flowClass A Common StockSEC:0001937915-25-000004:0
100,000 shares@ US$1.74100.0% of flowClass A Common StockSEC:0001521111-25-000003:0
10,000 shares@ US$1.71100.0% of flowClass A Common StockSEC:0001415889-25-017660:0
Canonical exit: 16 Sept 2025 (T+90)
50,000 shares@ US$1.807100.0% of flowClass A Common StockSEC:0001415889-25-017658:0
Canonical exit: 14 Sept 2025 (T+90)
25 of 52 declarations
关于 Nuvation Bio Inc.
Nuvation Bio Inc. 是一家总部位于美国纽约的生物制药公司，在美国纽约证券交易所/纳斯达克市场上市。该公司由知名的生物制药高管、Medivation前创始人David Hung医学博士于2018年创立，其战略是开发和收购针对高度未满足医疗需求的差异化肿瘤资产。其模式比广泛多元化的制药公司更专注：Nuvation Bio将自己定位为一家专业的肿瘤学公司，依靠具有创造临床和商业价值潜力的科学独特项目。 公司的核心业务围绕着一个规模虽小但具有战略重要性的产品线。其主要资产是taletrectinib，在美国以IBTROZI的名称销售，用于治疗某些晚期ROS1阳性非小细胞肺癌患者。该产品是公司发展中的关键转折点，因为它使Nuvation Bio在2025年从一家开发阶段的生物技术公司转型为一家商业化阶段的公司。除了IBTROZI，产品线还包括safusidenib（一种脑渗透性IDH1抑制剂）、NUV-1511（一种为靶向癌症治疗设计的创新药物偶联物）和NUV-868（一种BD2选择性BET抑制剂）。这些项目共同反映了以机制差异化肿瘤资产为中心的研究策略，而非大量早期押注。 从竞争角度来看，Nuvation Bio在医疗保健领域最具挑战性和最拥挤的细分市场之一运营。它与专业的生物技术公司以及拥有成熟肿瘤学业务的大型制药公司竞争。其相对优势在于其项目的科学特性、管理团队的经验以及对高需求治疗利基市场的关注。同时，与大多数中型生物技术公司一样，该公司仍面临临床、监管、商业化和融资风险，其估值将继续严重依赖执行和数据发布。 最近的发展加强了围绕主要资产的投资理由。2025年，FDA批准IBTROZI用于晚期ROS1阳性肺癌，为公司带来了首个商业收入来源。2026年，Nuvation Bio宣布FDA接受了一份补充申请，旨在更新标签上的疗效信息，并且该药物被添加到NCCN指南建议中，用于某些中枢神经系统癌症相关的使用案例。该公司还与Eisai签署了一项独家许可协议，涵盖欧洲和美国、中国、日本以外的其他地区，扩大了taletrectinib的潜在地理足迹。对于国际投资者而言，Nuvation Bio最好被视为一个肿瘤学转型故事：一家在美国上市的生物技术公司，拥有新兴的商业产品、不断扩大的地理机会以及仍提供有意义上行选择权的产品线。
